INS365 Ophthalmic drops: Phase III

In a U.S. placebo-controlled Phase III trial of INS365 in 558 patients with KCS, INS365 given as a 1% or 2% solution did not show superiority to placebo on the primary efficacy endpoint. ISPH said tha...